The role of molecular markers in personalized therapy of kidney cancer

Abstract

Here, we provide a general overview of the biology of renal cell carcinoma (RCC) and look into how the expression of certain markers affects the angiogenesis of human kidney cancer, which may aid in the development of renal carcinoma. Mainly explained genetic mutations or inactivations associated with RCC include those in VHL, which cause an influx of downstream oncogenic targets including HIFs. Downstream genes that are involved in cell proliferation, angiogenesis, and erythropoiesis, such as vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and carbonic anhydrase IX (CAIX), are expressed as a result of HIFs. We also made an effort to foresee some potential future advancements in the field of RCC research and investigate the potential relationship between these markers and individualized targeted therapy.